Ebixa 20mg may be prescribed at general hospitals in Korea

Alzheimer treatment Ebixa

Lands at medical institutions including SNUH, Severance Hospital, AMC, etc.

Improved convenience in administration with once-daily oral administration

The high-dose formulation of the Alzheimer’s treatment ‘Ebixa’ has landed at general hospitals in Korea.

 

According to industry sources, Lundbeck Korea’s ‘Ebixa (memantine) tablet 20mg’ passed the drug committees of medical institutions in Korea, including Seoul National University Hospital, Seoul Asan Medical Center, Sinchon Severance Hospital, and Seoul National University Bundang Hospital.

 

The drug has stably established a prescription environment in Korea since its launch in August last year.

 

Ebixa is an NMDA receptor antagonist approved for the treatment of moderate-to-severe Alzheimer’s disease.

 

It blocks glutamate, a neurotransmitter involved in learning and memory, to prevent or slow down the progression of the disease.

 

It is used to treat Alzheimer’s disease in patients with an MMSE total score of 20 or lower and CDR2-3 or GDS 4-7 accompanied by cerebrovascular disease.

 

Ebixa 20mg is a new formulation that increased the dose by 2 times from the existing 10mg dose.

 

If the original Ebixate 10mg had to be administered twice a day based on the maintenance dose for healthy adults, the 20mg can be orally administered once a day, improving the patient's medication compliance through simplification of the regimen.

 

However, the 20mg dose should be administered at the same time every day and can be administered up to twice a day if necessary.

 

Pharmacokinetic tests and comparative trials that administered Ebixa 20mg once a day showed that its safety and efficacy were similar to the twice-a-day oral administration of the existing Ebixa 10mg formulation.

 

As a result, Ebixa 20mg reduces the burden of dementia patients having to remember the time and frequency of taking medications and reduces the possibility of them taking incorrect medications.

 

Ebixa 20mg’s safety and efficacy have been confirmed through pharmacokinetic tests and comparative clinical trials.

 

In May 2008, the drug was approved for once-daily use by the EMA and approved for use as once-daily use in 30 European countries, Argentina, Mexico, Turkey, Singapore, Japan, and Australia.